|drug2581||Plasma from a volunteer donor Wiki||1.00|
|drug2954||SARS-CoV-2 convalescent plasma Wiki||0.58|
|D014786||Vision Disorders NIH||0.71|
|D015354||Vision, Low NIH||0.71|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Prompted by the current COVID-19 pandemic, the American Academy of Ophthalmology has recommended the use of telemedicine to continue ophthalmic care while maintaining patient and provider social distancing. As part of remote examinations, patients may be expected to perform home eye testing for visual acuity and the use of various home visual acuity charts have been proposed to provide clinicians with this vital data. However, the use of home visual acuity exams has not been validated in our patient population. This project aims to determine the efficacy and validity of measuring visual acuity at home with a printed-out ETDRS chart.
Description: Best Visual Acuity per eyeMeasure: Best Corrected Visual Acuity (BCVA) Per Eye Time: From the time they sign the consent until we take their BCVA in clinic. Approximately 1-2 weeks.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports